文献速递肝病

原发性胆汁性胆管炎肝移植后预防性UDCA治疗的长期影响

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
PubMed 文献 · J Hepatol · 2020-04-07

该回顾性队列研究纳入16中心780例因PBC行肝移植患者,随访中位11年,其中190例接受预防性UDCA(10-15 mg/kg/日)。预防性UDCA与PBC复发、移植物丢失、肝病死亡及全因死亡风险降低相关,RMST分析显示20年生存获益2.26年。环孢素联合预防性UDCA方案与最低复发和死亡风险相关。

要点

  • 预防性UDCA降低PBC肝移植后复发风险(aHR 0.41)。
  • 预防性UDCA降低移植物丢失、肝病死亡和全因死亡风险。
  • 环孢素联合预防性UDCA方案预后最佳。

核心结论

  • PBC肝移植后预防性UDCA与疾病复发、移植物丢失及死亡风险降低相关。
  • 环孢素联合预防性UDCA方案与最低的PBC复发和死亡风险相关。

研究设计与样本

  • 回顾性队列研究,纳入1983-2017年16中心(9国)780例因PBC行肝移植患者,中位随访11年。
  • 其中190例接受预防性UDCA(10-15 mg/kg/日)。
  • 主要结局为PBC复发的组织学证据,次要结局为移植物丢失、肝病死亡和全因死亡。
  • 采用多变量校正Cox和限制性平均生存时间(RMST)模型分析。

主要发现

  • PBC复发显著缩短移植物和患者生存。
  • 预防性UDCA与PBC复发风险降低相关(aHR 0.41;95% CI 0.28-0.61;p<0.0001)。
  • 预防性UDCA与移植物丢失风险降低相关(aHR 0.33;95% CI 0.13-0.82;p<0.05)。
  • 预防性UDCA与肝病死亡风险降低相关(aHR 0.46;95% CI 0.22-0.98;p<0.05)。
  • 预防性UDCA与全因死亡风险降低相关(aHR 0.69;95% CI 0.49-0.96;p<0.05)。

关键数值与推荐

  • 预防性UDCA剂量为10-15 mg/kg/日。
  • PBC复发aHR 0.41(95% CI 0.28-0.61;p<0.0001)。
  • 移植物丢失aHR 0.33(95% CI 0.13-0.82;p<0.05)。
  • 肝病死亡aHR 0.46(95% CI 0.22-0.98;p<0.05)。
  • 全因死亡aHR 0.69(95% CI 0.49-0.96;p<0.05)。

临床怎么用

  • PBC患者肝移植后可考虑预防性使用UDCA(10-15 mg/kg/日)以降低复发和死亡风险。
  • 免疫抑制方案可优先考虑环孢素联合预防性UDCA。

局限性

  • 回顾性队列设计。
  • 预防性UDCA组样本量较小(190例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT) is frequent and can impair graft and patient survival. Ursodeoxycholic acid (UDCA) is the current standard therapy for PBC. We investigated the effect of preventive exposure to UDCA on the incidence and long-term consequences of PBC recurrence after LT. METHODS: We performed a retrospective cohort study in 780 patients transplanted for PBC, between 1983-2017 in 16 centers (9 countries), and followed-up for a median of 11 years. Among them, 190 received preventive UDCA (10-15 mg/kg/day). The primary outcome was histological evidence of PBC recurrence. The secondary outcomes were graft loss, liver-related death, and all-cause death. The association between preventive UDCA and outcomes was quantified using multivariable-adjusted Cox and restricted mean survival time (RMST) models. RESULTS: While recurrence of PBC significantly shortened graft and patient survival, preventive exposure to UDCA was associated with reduced risk of PBC recurrence (adjusted hazard ratio [aHR] 0.41; 95% CI 0.28-0.61; p <0.0001), graft loss (aHR 0.33; 95% CI 0.13-0.82; p <0.05), liver-related death (aHR 0.46; 95% CI 0.22-0.98; p <0.05), and all-cause death (aHR 0.69; 95% CI 0.49-0.96; p <0.05). On RMST analysis, preventive UDCA led to a survival gain of 2.26 years (95% CI 1.28-3.25) over a period of 20 years. Exposure to cyclosporine rather than tacrolimus had a complementary protective effect alongside preventive UDCA, reducing the cumulative incidence of PBC recurrence and all-cause death. CONCLUSIONS: Preventive UDCA after LT for PBC is associated with a reduced risk of disease recurrence, graft loss, and death. A regimen combining cyclosporine and preventive UDCA is associated with the lowest risk of PBC recurrence and mortality. LAY SUMMARY: Recurrence of primary biliary cholangitis after liver transplantation is frequent and can impair graft and patient survival. We performed the largest international study of transplanted patients with primary biliary cholangitis to date. Preventive administration of ursodeoxycholic acid after liver transplantation was associated with reduced risk of disease recurrence, graft loss, liver-related and all-cause mortality. A regimen combining cyclosporine and preventive ursodeoxycholic acid was associated with the best outcomes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Corpechot C, Chazouillères O, Belnou P, et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol. 2020. PMID: 32275981. doi:10.1016/j.jhep.2020.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。